Back to top
more

Kodiak Sciences (KOD)

(Delayed Data from NSDQ)

$4.76 USD

4.76
603,466

+0.38 (8.68%)

Updated Nov 6, 2024 04:00 PM ET

After-Market: $4.76 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value A Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (95 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks News

Kodiak (KOD) Down as Late-Stage DME Studies Fail

Kodiak (KOD) stock plunges as it failed to meet the primary endpoint in phase III studies evaluating tarcocimab in diabetic macular edema patients.

Why Is Kodiak Sciences Inc. (KOD) Up 62.9% Since Last Earnings Report?

Kodiak Sciences Inc. (KOD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Kodiak (KOD) Advances With Tarcocimab Amid Stiff Competition

Kodiak (KOD) focuses on completing ongoing studies on tarcocimab for several retinal indications. However, competition in the market and the lack of other candidates in the pipeline are concerns.

Kodiak's (KOD) Q1 Earnings Miss, Pipeline in Focus, Stock Up

Despite poor first-quarter performance, Kodiak (KOD) stock rises 13% on the strong pace of the tarcocimab clinical programs.

Why Is Kodiak Sciences Inc. (KOD) Down 26.3% Since Last Earnings Report?

Kodiak Sciences Inc. (KOD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Immunic's (IMUX) Ulcerative Colitis Study Shows Positive Data

Immunic (IMUX) reports positive results from the maintenance phase of the phase II study evaluating its lead candidate, vidofludimus calcium, to treat patients with ulcerative colitis.

Palisade (PALI) Enrolls First Patient in LB1148 Study in China

Palisade's (PALI) development partner, Newsoara, enrolls first patient in the late-stage clinical study of LB1148 to improve postoperative GI function for patients in China.

InflaRx (IFRX) Stock Up on FDA's EUA for COVID-19 Treatment

InflaRx (IFRX) shares gain as it receives emergency-use authorization from the FDA for Gohibic (vilobelimab) to treat COVID-19 in terminally-ill patients.

Kodiak (KOD) Treats First Patient in Diabetic Macular Edema Study

Kodiak (KOD) has its first patient in the early-stage study of KSI-501 for treating retinal diseases.

Kodiak Sciences (KOD) Shares are Up 26% in a Week: Here's Why

Shares of Kodiak Sciences (KOD) shot up 26% in the last week after the company announced remaining on track with ongoing studies in its fourth-quarter and full-year 2022 earnings report.

Kodiak Sciences Inc. (KOD) Up 1% Since Last Earnings Report: Can It Continue?

Kodiak Sciences Inc. (KOD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Does Kodiak Sciences Inc. (KOD) Have the Potential to Rally 87% as Wall Street Analysts Expect?

The consensus price target hints at an 87.4% upside potential for Kodiak Sciences Inc. (KOD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts See a 72% Upside in Kodiak Sciences Inc. (KOD): Can the Stock Really Move This High?

The consensus price target hints at a 72% upside potential for Kodiak Sciences Inc. (KOD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Kodiak Sciences' (KOD) Q3 Earnings Beat, Eye Candidate in Focus

Kodiak Sciences (KOD) reports a narrower-than-expected loss for the third quarter of 2022. The focus is on the lead candidate, KSI-301, developed for treating various retinal vascular diseases.

Axsome (AXSM) Q3 Loss Narrower Than Expected, Revenues Miss

Axsome (AXSM) reports a narrower-than-expected loss in the third quarter. Revenues comprise sales of the sleep drug, Sunosi, acquired from Jazz.

Amicus (FOLD) Q3 Earnings Beat, Galafold Sales Miss Estimates

Amicus Therapeutics (FOLD) posts a narrower-than-expected loss in the third quarter. FOLD's sole marketed drug Galafold's solid sales drive the top line.

Intra-Cellular (ITCI) Beat on Q3 Earnings and Sales Estimates

Intra-Cellular Therapeutics (ITCI) posts a narrower-than-expected Q3 loss and sales also beat the mark. ITCI continues to advance its pipeline with developmental programs.

Agios (AGIO) Q3 Loss Narrower Than Expected, Sales Miss

Agios Pharmaceuticals (AGIO) posts narrower-than-expected Q3 loss while sales miss estimates. The company is enrolling participants across five pivotal studies evaluating the lead drug Pyrukynd.

Intellia's (NTLA) Q3 Loss Wider Than Expected, Revenues Up Y/Y

Intellia Therapeutics (NTLA) posts a wider-than-expected Q3 loss and sales also miss the mark. NTLA continues to advance its pipeline with developmental programs.

Ultragenyx's (RARE) Q3 Earnings Miss Estimates, Revenues Up Y/Y

Ultragenyx (RARE) reports a wider-than-expected loss in the third quarter. Revenues, though up year over year, miss estimates.

Repligen (RGEN) Beats Q3 Earnings Estimate, Ups 2022 Guidance

Repligen (RGEN) reports encouraging third-quarter results, with sales and earnings beating estimates. RGEN also raises its financial guidance for 2022

Why Is Kodiak Sciences Inc. (KOD) Down 23.8% Since Last Earnings Report?

Kodiak Sciences Inc. (KOD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Kodiak Sciences (KOD) Rises 60% in Past 3 Months: Here's Why

Kodiak Sciences (KOD) has progressed well with the development of its lead pipeline candidate, tarcocimab, for treating various retinal vascular diseases.

Kodiak Sciences (KOD) Focuses on Developing Eye Drug Tarcocimab

Kodiak Sciences (KOD) lead pipeline candidate, tarcocimab, being developed for treating various retinal vascular diseases, holds potential. Stiff competition in the market remains a woe.

Kodiak Sciences (KOD) Q2 Earnings Beat, Eye Candidate in Focus

Kodiak Sciences (KOD) reports narrower-than-expected loss for the second quarter of 2022. The focus is on the lead candidate, KSI-301, which is being developed for treating various retinal vascular diseases.